RANDOMISED COMPARISON OF CYCLOPHOSPHAMIDE VERSUS IFOSFAMIDE CONTAINING ADJUVANT CHEMOTHERAPY (CTX) IN STANDARD RISK (SR) EWING SARCOMA (ES) PATIENTS: RESULTS OF THE EURO EWING-99 TRIAL

被引：0
|
作者：
Dirksen, Uta
LeDeley, Marie-Cecile [2 ]
Whelan, Jeremy [3 ]
Paulussen, Michael [4 ]
Oberlin, Odile [5 ]
Lewis, Ian [6 ]
Ranft, Andreas
Michon, Jean [7 ]
Ladenstein, Ruth [8 ]
Brennan, Bernadette [1 ]
Perinne, Marec Berard [9 ]
Van den Berg, Henk [10 ]
Hjorth, Lars [11 ]
Wheatley, Keith [12 ]
Douglas, Caroline [13 ]
Van Glabbeke, Martine [14 ]
Judson, Ian [15 ]
Craft, Alan [16 ]
Juergens, Heribert [17 ]
机构：
[1] Royal Manchester Childrens Hosp, Univ Hosp Munster, Munster, Germany
[2] Inst Gustave Roussy, Serv Biostat & Epidemiol, Paris, France
[3] Middlesex Hosp, Dept Oncol, London, England
[4] Vest Kinderklin, Datteln, Germany
[5] Inst Gustave Roussy, Dept Pediat, Paris, France
[6] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England
[7] Inst Curie, Dept Oncol, Paris, France
[8] St Anna Childrens Hosp & Res Inst, Univ Hosp Vienna, Vienna, Austria
[9] Ctr Leon Berard, Inst Hematooncol Pediat, F-69373 Lyon, France
[10] Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands
[11] Univ Lund Hosp, S-22185 Lund, Sweden
[12] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
[13] Univ Leicester, CCLG Data Ctr, Leicester, Leics, England
[14] Eortc Data Ctr, European Org Res & Treatment Canc Headquarters, Brussels, Belgium
[15] He Royal Marsden NHS Fdn Trust, London, England
[16] Royal Victoria Infirm, Sir James Spence Inst, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
[17] Univ Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2011年 / 57卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：710 / 710
页数：1
相关论文
共 25 条
  • [21] Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60 - Report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years
    Bacci, Gaetano
    Balladelli, Alba
    Forni, Cristiana
    Ferrari, Stefano
    Longhi, Alessandra
    Bacchini, Patrizia
    Alberghini, Marco
    Fabbri, Nicola
    Benassi, MariaSerena
    Briccoli, Antonio
    Picci, Piero
    [J]. CANCER, 2007, 109 (04) : 780 - 786
  • [22] ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
    Susanna Slater
    Annette Bryant
    Hsiang-Chi Chen
    Ruwaida Begum
    Isma Rana
    Maria Aresu
    Clare Peckitt
    Oleg Zhitkov
    Retchel Lazaro-Alcausi
    Victoria Borja
    Rachel Powell
    David Lowery
    Michael Hubank
    Thereasa Rich
    Gayathri Anandappa
    Ian Chau
    Naureen Starling
    David Cunningham
    [J]. BMC Cancer, 23
  • [23] ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
    Slater, Susanna
    Bryant, Annette
    Chen, Hsiang-Chi
    Begum, Ruwaida
    Rana, Isma
    Aresu, Maria
    Peckitt, Clare
    Zhitkov, Oleg
    Lazaro-Alcausi, Retchel
    Borja, Victoria
    Powell, Rachel
    Lowery, David
    Hubank, Michael
    Rich, Thereasa
    Anandappa, Gayathri
    Chau, Ian
    Starling, Naureen
    Cunningham, David
    [J]. BMC CANCER, 2023, 23 (01)
  • [24] Final results from a randomised phase II study comparing epirubicin plus cyclophosphamide (EC) or CMF versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly non-frail breast cancer patients with an increased risk of relapse
    von Minckwitz, G.
    Conrad, B.
    Decker, T.
    Reimer, T.
    Hackmann, J.
    Potenberg, J.
    Bauer, W.
    Jackisch, C.
    Nekljudova, V.
    Loibl, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S109 - S109
  • [25] Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group
    Eiermann, Wolfgang
    Graf, Erika
    Ataseven, Beyhan
    Conrad, Bettina
    Hilfrich, Joern
    Massinger-Biebl, Heidi
    Vescia, Sabine
    Loibl, Sibylle
    von Minckwitz, Gunter
    Schumacher, Martin
    Kaufmann, Manfred
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 84 - 94
123